ABOUT US - INSICA

INSICA Steering Group

Nyall R. London, Jr. (INSICA President; 2024-2026),

Robbie Woods (EUSICA President; 2025-2027),

Garret Choby (CORSICA Representative),

Matt Lechner (INSICA Founding President; 2019-2024),

Glenn J. Hanna (INSICA President-Elect; 2026-2028)

Advisory Committee and Subspecialty Representatives: Melvin Chua (NPC), Gary Gallia (Neurosurgery), TBC (Histopathology), TBC (Radiation Oncology), Amie Mertens (Trustee, Head and Neck Cancer Research Trust), TBC (patient representative)

The International Network for Sinonasal Cancer Research was initially founded in 2019 with a primary objective of facilitating large multi-institutional international collaborative retrospective studies. INSICA is led by the above steering group and annual meetings have been held since 2022, combined with the European Network for Sinonasal Cancer Research (EUSICA) in Madrid, Copenhagen, London, and Paris, with the 2026 annual meeting planned for Bethesda, Maryland. The first study arising from INSICA collaborative efforts included 12 institutions from the United States, United Kingdom, and Europe and amassed clinical data from 404 patients with olfactory neuroblastoma (ONB), by far the largest retrospective study for this rare sinonasal malignancy. Further studies followed and these initial INSICA efforts highlight the value and importance of multi-institutional collaborative studies for advancing evidence-based management of rare sinonasal tumors. INSICA has been greatly supported by the Head and Neck Cancer Research Trust and has been growing steadily over the years.On April 12, 2025, the INSICA group held the first international clinical trial planning meeting at L’Hôpital Lariboisière in Paris, France. The clinical trial planning meeting was led by Nyall R. London and Glenn J. Hanna with participating members also including Neal S. Akhave, Lot Devriese, François Régis Ferrand , Gary L. Gallia, Lifeng Li, Antoine Moya-Plana, Teppei Takeda, Juliette Thariat, Benjamin Verillaud, Robbie Woods, and Matt Lechner. These members included specialists from Otolaryngology, Medical Oncology, Radiation Oncology, and Neurosurgery. The meeting was preceded by submission of trial ideas by attendees and selection of clinical trial proposals and consensus recommendations to discuss. The outcomes of this meeting and a consensus statement have been submitted for publication.Our aim is that the network’s collaborative research output (below publications) guide national and international organizations when establishing updated guidelines on the diagnosis and management of these malignancies. Moreover, INSICA have also been advocating the harmonisation of prospective data collection between various large collaborations with the aim to create even larger, global datasets on many orphan diseases.We embrace a new emphasis on development of collaborative interventional trials as well as the development of recommendations to guide use of emerging molecularly targeted therapies. We invite all interested members of the scientific community with an interest in this challenging area of research and clinical practice to join us and engage in this highly interesting field.